Skip to main content
ATOSSA THERAPEUTICS, INC. logo

ATOSSA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ATOS ISIN · US04962H5063 US Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2014-02-14 Director's Dealing
Country US United States of America
Listing US ATOS

About ATOSSA THERAPEUTICS, INC.

https://atossatherapeutics.com/

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative medicines for areas of significant unmet medical need, with a primary focus on oncology. The company is dedicated to addressing the full continuum of breast cancer care. Its lead program is centered on (Z)-endoxifen, a proprietary and potent selective estrogen receptor modulator (SERM). Atossa is advancing (Z)-endoxifen through clinical development for multiple breast cancer indications, including metastatic disease, aiming to provide a therapeutic with a potentially improved efficacy and tolerability profile.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2014-02-14 English
PRIMARY DOCUMENT
Director's Dealing
2014-02-14 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans. It includes details about the securities to be registered, the registration fee calculation, incorporation by reference of other SEC filings, and indemnification provisions for directors and officers. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories.
2014-02-14 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The text specifically reports the departure of a board member, John Barnhart, and the intention to appoint a new board member. This corresponds to announcements about changes in the company's board of directors. The document does not contain financial data or other report types, but rather a management/board change announcement. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and focused solely on this topic, confirming the classification with high confidence.
2014-02-05 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5), which is a type of SEC filing used to provide details about a securities offering. It describes the terms of an offering of units consisting of common stock and warrants, including pricing, placement agent fees, and use of proceeds. The document includes detailed information about the offering, risk factors, and legal matters related to the securities issuance. This type of document is specifically related to capital raising activities and financing updates. It is not an annual report, earnings release, or any other type of financial report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus supplement, not just an announcement or a brief notice, so it is not RPA or RNS. Confidence is high given the clear identification of the document as a Rule 424(b)(5) prospectus supplement related to a securities offering.
2014-01-24 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 24, 2014, by Atossa Genetics Inc. It details a public offering of units consisting of common stock and warrants, including terms of the offering, placement agency agreement, and related warrants. The content focuses on a financing event, specifically a best efforts public offering and related agreements. There are no financial statements or earnings data presented, nor is this a report of voting results, management changes, or legal proceedings. The primary subject is the company's capital raising activity through issuance of securities. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the financing transaction, not merely an announcement or reference to a report, so it is not an RPA or RNS. Confidence is high given the clear focus on financing terms and agreements.
2014-01-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.